Augment with Bupropion or Consider Cognitive Behavioral Therapy
For a patient with depression and anxiety on sertraline and rasagiline for Parkinson's disease, augment the current sertraline regimen with bupropion as the preferred non-serotonergic pharmacological option, or alternatively implement cognitive behavioral therapy (CBT) as a non-pharmacological strategy.
Rationale for Bupropion Augmentation
The 2023 American College of Physicians guideline provides moderate-certainty evidence that bupropion augmentation of an existing SSRI (like sertraline) achieves similar efficacy to other augmentation strategies for treatment-resistant depression 1. Critically, bupropion augmentation demonstrated significantly lower discontinuation rates due to adverse events (12.5%) compared to buspirone augmentation (20.6%; P < 0.001) in the STAR*D trial 1.
Why Bupropion is Ideal in This Context:
- Non-serotonergic mechanism: Works via dopamine and norepinephrine reuptake inhibition, avoiding additional serotonergic burden
- No serotonin syndrome risk: Critical given the patient is already on sertraline, and rasagiline (an MAO-B inhibitor) carries theoretical serotonergic interaction concerns 2, 3
- Potential benefits for PD: May address apathy, which commonly coexists with depression in Parkinson's disease 4
- Better tolerability profile: Lower adverse event discontinuation rates compared to other augmentation agents 1
Critical Safety Consideration: Serotonin Syndrome Risk
You must be vigilant about serotonin syndrome given the combination of sertraline (SSRI) and rasagiline (MAO-B inhibitor). The sertraline FDA label explicitly warns about potentially life-threatening serotonin syndrome when SSRIs are combined with MAOIs, including MAO-B inhibitors 2. While rasagiline at therapeutic doses (≤1 mg/day) is generally considered selective for MAO-B, this selectivity diminishes at higher doses, and the combination still warrants close monitoring 3.
Monitor for serotonin syndrome symptoms:
- Mental status changes (agitation, confusion, delirium)
- Autonomic instability (tachycardia, labile blood pressure, hyperthermia)
- Neuromuscular symptoms (tremor, rigidity, myoclonus, hyperreflexia)
- GI symptoms (nausea, vomiting, diarrhea)
Alternative Non-Pharmacological Option: Cognitive Behavioral Therapy
CBT represents the strongest non-pharmacological evidence for depression treatment and can be used either as augmentation or as an alternative to medication escalation 1. The STAR*D trial demonstrated that augmenting citalopram with CBT achieved similar efficacy to medication augmentation, with numerically lower discontinuation rates due to adverse events (9.2% vs. 18.8% for medication; P = 0.086) 1.
CBT is particularly valuable in Parkinson's disease patients because:
- Addresses both depression and anxiety without adding medication burden
- No drug-drug interaction concerns
- Evidence supports effectiveness specifically in PD populations 5, 6, 7
- Can be combined with physical exercise for additive benefits 8, 9
Other Non-Serotonergic Considerations
Dopaminergic Optimization
Before adding another antidepressant, ensure the patient's Parkinson's motor symptoms are optimally controlled. Inadequately treated motor symptoms can worsen depression, and optimizing levodopa or dopamine agonist therapy may improve mood 6, 7. However, be aware that rasagiline itself can cause or worsen psychiatric symptoms including depression, anxiety, hallucinations, and psychotic-like behavior 3.
Tricyclic Antidepressants (TCAs)
Nortriptyline and desipramine have evidence in PD depression 6, 4, but their anticholinergic effects can worsen cognitive function and constipation—common problems in PD 4. Avoid TCAs in this population unless other options have failed.
SNRIs (Venlafaxine, Duloxetine)
While venlafaxine has evidence for PD depression 6, 4, it adds serotonergic activity, which is contraindicated given your goal of non-serotonergic options and the existing serotonin syndrome risk with sertraline plus rasagiline.
Practical Implementation Algorithm
First, assess current medication optimization:
- Is sertraline at an adequate dose (typically 100-200 mg/day for depression)?
- Are PD motor symptoms well-controlled on current rasagiline dose?
- Any signs/symptoms of serotonin syndrome currently?
If sertraline is optimized but inadequate response:
- Add bupropion SR/XL starting at 150 mg daily, titrating to 300-450 mg/day as tolerated
- Monitor for seizure risk (contraindicated if seizure history)
- Watch for worsening tremor (bupropion can occasionally worsen tremor)
If patient prefers non-pharmacological approach or has medication concerns:
Monitor closely for:
- Serotonin syndrome symptoms (especially first 2-4 weeks after any dose change)
- Worsening psychiatric symptoms from rasagiline (hallucinations, psychosis, impulse control disorders) 3
- Treatment response at 4-6 weeks
Common Pitfalls to Avoid
- Do not add another serotonergic agent (e.g., SNRI, mirtazapine, buspirone) given the existing sertraline + rasagiline combination
- Do not use tramadol, triptans, or St. John's Wort in this patient—all increase serotonin syndrome risk 2
- Do not assume rasagiline is benign psychiatrically—it can cause or worsen depression, anxiety, hallucinations, and impulse control disorders 3
- Do not overlook non-motor fluctuations—depression/anxiety may worsen during "off" periods and improve with dopaminergic optimization 7